Kronos Bio, Inc. (KRON)

0.7425 +0.0155 (+2.13%) At close: 04:00PM EDT

Kronos Bio, Inc.

1300 South El Camino Real
Suite 400
San Mateo, CA 94402
United States
(650) 781-5200
https://www.kronosbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 61

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Norbert W. Bischofberger Ph.D.	President, CEO & Director	912.2k	N/A	1956
Mr. Joshua A. Kazam	Co-Founder & Director	40k	N/A	1977
Mr. David M. Tanen J.D.	Secretary & Director	40k	N/A	1971

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Corporate governance

Kronos Bio, Inc.’s ISS governance QualityScore as of 1 June 2024 is 9. The pillar scores are Audit: 9; Board: 10; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.